310 related articles for article (PubMed ID: 35819272)
1. Facts and Hopes for Immunotherapy in Renal Cell Carcinoma.
Yao C; Zhang T; Wu T; Brugarolas J
Clin Cancer Res; 2022 Dec; 28(23):5013-5020. PubMed ID: 35819272
[TBL] [Abstract][Full Text] [Related]
2. Significance of tumor microenvironment in acquiring resistance to vascular endothelial growth factor-tyrosine kinase inhibitor and recent advance of systemic treatment of clear cell renal cell carcinoma.
Mikami S; Mizuno R; Kosaka T; Tanaka N; Kuroda N; Nagashima Y; Okada Y; Oya M
Pathol Int; 2020 Oct; 70(10):712-723. PubMed ID: 32652869
[TBL] [Abstract][Full Text] [Related]
3. Current Status and Future Directions of Immunotherapy in Renal Cell Carcinoma.
Considine B; Hurwitz ME
Curr Oncol Rep; 2019 Mar; 21(4):34. PubMed ID: 30848378
[TBL] [Abstract][Full Text] [Related]
4. Checkpoint Inhibitors for the Treatment of Renal Cell Carcinoma.
Ghatalia P; Zibelman M; Geynisman DM; Plimack ER
Curr Treat Options Oncol; 2017 Jan; 18(1):7. PubMed ID: 28210995
[TBL] [Abstract][Full Text] [Related]
5. [Immunotherapy Based on Tumor Microenvironment in Renal Cell Carcinoma].
Han SC; Yin HQ; Xu T
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2022 Apr; 44(2):305-312. PubMed ID: 35538767
[TBL] [Abstract][Full Text] [Related]
6. Angiogenic and immunological pathways in metastatic renal cell carcinoma: A counteracting paradigm or two faces of the same medal? The GIANUS Review.
Bracarda S; Porta C; Sabbatini R; Rivoltini L
Crit Rev Oncol Hematol; 2019 Jul; 139():149-157. PubMed ID: 30424938
[TBL] [Abstract][Full Text] [Related]
7. Emerging monoclonal antibodies for the treatment of renal cell carcinoma (RCC).
Atkins MB; Philips GK
Expert Opin Emerg Drugs; 2016 Sep; 21(3):243-54. PubMed ID: 27539246
[TBL] [Abstract][Full Text] [Related]
8. Tumor and immune reprogramming during immunotherapy in advanced renal cell carcinoma.
Bi K; He MX; Bakouny Z; Kanodia A; Napolitano S; Wu J; Grimaldi G; Braun DA; Cuoco MS; Mayorga A; DelloStritto L; Bouchard G; Steinharter J; Tewari AK; Vokes NI; Shannon E; Sun M; Park J; Chang SL; McGregor BA; Haq R; Denize T; Signoretti S; Guerriero JL; Vigneau S; Rozenblatt-Rosen O; Rotem A; Regev A; Choueiri TK; Van Allen EM
Cancer Cell; 2021 May; 39(5):649-661.e5. PubMed ID: 33711272
[TBL] [Abstract][Full Text] [Related]
9. Metastatic renal cell carcinoma imaging evaluation in the era of anti-angiogenic therapies.
Sirous R; Henegan JC; Zhang X; Howard CM; Souza F; Smith AD
Abdom Radiol (NY); 2016 Jun; 41(6):1086-99. PubMed ID: 27193601
[TBL] [Abstract][Full Text] [Related]
10. The Past, Present and Future of Immunotherapy for Metastatic Renal Cell Carcinoma.
Chang AJ; Zhao L; Zhu Z; Boulanger K; Xiao H; Wakefield MR; Bai Q; Fang Y
Anticancer Res; 2019 Jun; 39(6):2683-2687. PubMed ID: 31177102
[TBL] [Abstract][Full Text] [Related]
11. Integrated analysis of immune-related gene subtype and immune index for immunotherapy in clear cell renal cell carcinoma.
Bai D; Chen S; Feng H; Yin A; Lu J; Ma Y; Sugiyama H
Pathol Res Pract; 2021 Sep; 225():153557. PubMed ID: 34329838
[TBL] [Abstract][Full Text] [Related]
12. Multidiscipline Immunotherapy-Based Rational Combinations for Robust and Durable Efficacy in Brain Metastases from Renal Cell Carcinoma.
Lee HW
Int J Mol Sci; 2021 Jun; 22(12):. PubMed ID: 34208157
[TBL] [Abstract][Full Text] [Related]
13. Immunological heterogeneity of the RCC microenvironment: do targeted therapies influence immune response?
Bex A; Etto T; Vyth-Dreese F; Blank C; Griffioen AW
Curr Oncol Rep; 2012 Jun; 14(3):230-9. PubMed ID: 22362358
[TBL] [Abstract][Full Text] [Related]
14. Epigenetics in advanced renal cell carcinoma: Potential new targets.
Molina-Cerrillo J; Santoni M; Ruiz Á; Massari F; Pozas J; Ortego I; Gómez V; Grande E; Alonso-Gordoa T
Crit Rev Oncol Hematol; 2022 Dec; 180():103857. PubMed ID: 36257538
[TBL] [Abstract][Full Text] [Related]
15. Future perspectives in melanoma research : Meeting report from the "Melanoma Bridge". Napoli, December 1st-4th 2015.
Ascierto PA; Agarwala S; Botti G; Cesano A; Ciliberto G; Davies MA; Demaria S; Dummer R; Eggermont AM; Ferrone S; Fu YX; Gajewski TF; Garbe C; Huber V; Khleif S; Krauthammer M; Lo RS; Masucci G; Palmieri G; Postow M; Puzanov I; Silk A; Spranger S; Stroncek DF; Tarhini A; Taube JM; Testori A; Wang E; Wargo JA; Yee C; Zarour H; Zitvogel L; Fox BA; Mozzillo N; Marincola FM; Thurin M
J Transl Med; 2016 Nov; 14(1):313. PubMed ID: 27846884
[TBL] [Abstract][Full Text] [Related]
16. Clinical activity of immunotherapy-based combination first-line therapies for metastatic renal cell carcinoma: the right treatment for the right patient.
Borchiellini D; Maillet D
Bull Cancer; 2022 May; 109(2S):2S4-2S18. PubMed ID: 35760470
[TBL] [Abstract][Full Text] [Related]
17. Novel immunotherapeutic strategies in development for renal cell carcinoma.
Inman BA; Harrison MR; George DJ
Eur Urol; 2013 May; 63(5):881-9. PubMed ID: 23084331
[TBL] [Abstract][Full Text] [Related]
18. New anti-angiogenic targeted therapy in advanced renal cell carcinoma (RCC): current status and future prospects.
Sciarra A; Gentile V; Salciccia S; Alfarone A; Di Silverio F
Rev Recent Clin Trials; 2008 May; 3(2):97-103. PubMed ID: 18474019
[TBL] [Abstract][Full Text] [Related]
19. The society for immunotherapy of cancer consensus statement on immunotherapy for the treatment of advanced renal cell carcinoma (RCC).
Rini BI; Battle D; Figlin RA; George DJ; Hammers H; Hutson T; Jonasch E; Joseph RW; McDermott DF; Motzer RJ; Pal SK; Pantuck AJ; Quinn DI; Seery V; Voss MH; Wood CG; Wood LS; Atkins MB
J Immunother Cancer; 2019 Dec; 7(1):354. PubMed ID: 31856918
[TBL] [Abstract][Full Text] [Related]
20. Comprehensive analysis of cellular senescence-related genes in the prognosis, tumor microenvironment, and immunotherapy/chemotherapy of clear cell renal cell carcinoma.
Lu C; Wang Y; Nie L; Chen L; Li M; Qing H; Li S; Wu S; Wang Z
Front Immunol; 2022; 13():934243. PubMed ID: 36189255
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]